Cytomegalovirus Clinical Trials

58 clinical trials for Cytomegalovirus across international registries, including 18 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection — RECRUITING
• Comparison Diagnostic Tests for the Diagnosis of CYTOmegalovirus Organ Disease in Patients With intestinalBOweL Diseases — RECRUITING
• A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina — RECRUITING
• A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) — RECRUITING · PHASE3
• Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT — RECRUITING · PHASE1
• Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients — RECRUITING · PHASE3
• A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections — RECRUITING · PHASE3
• Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation — RECRUITING · PHASE2
• Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective — RECRUITING
• Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) — RECRUITING · PHASE4
• A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation — RECRUITING
• Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies — RECRUITING · PHASE2
• A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea — RECRUITING
• LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION — RECRUITING
• A PHASE 3, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF MRNA-1647 CYTOMEGALOVIRUS (CMV) VACCINE IN HEALTHY PARTICIPANTS 16 TO 40 YEARS OF AGE — RECRUITING · PHASE3
• DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY AND IMMUNOGENICITY OF A 2-DOSE AND A 3-DOSE REGIMEN OF V160 (CYTOMEGALOVIRUS [CMV] VACCINE) IN HEALTHY SERONEGATIVE WOMEN, 16 TO 35 YEARS OF AGE — RECRUITING · PHASE2
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF MARIBAVIR COMPARED TO VALGANCICLOVIR FOR THE TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL TO EVALUATE THE PROECTIVE EFFICACY AND SAFETY OF A THERAPUTIC VACCINE, ASPO113, IN CYTOMEGALOVIRUS (CMV)- SEROPOSTIVIVE RECIPIENTS UNDERGOING ALLOGENIC, HEMATOPOIETIC CELL TRANSPLANT (HCT). — RECRUITING · PHASE3
• The long term antibody response to CMV gB vaccine, in patients requiring liver or renal transplant. — COMPLETED · PHASE2
• A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium — ACTIVE_NOT_RECRUITING
• Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II — NOT_YET_RECRUITING · PHASE2
• Detection of Human Cytomegalovirus in the Saliva — COMPLETED
• A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age — COMPLETED · PHASE1
• A Study of Modified mRNA Vaccines in Healthy Adults — COMPLETED · PHASE1
• A Study of Cytomegalovirus (CMV) Infection After Kidney Transplant in Adults in the United Kingdom — COMPLETED
• CLEAR-CMV: COMBINATION LETERMOVIR AND STANDARD OF CARE ANTIVIRAL FOR ENHANCED ANTIVIRAL RESPONSE IN CYTOMEGALOVIRUS INFECTION IN LUNG TRANSPLANT RECIPIENTS: A PILOT TRIAL [PLACEBO CONTROLLED] — NOT_YET_RECRUITING
• A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection — COMPLETED
• Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients — COMPLETED · NA
• A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. — TERMINATED · PHASE2
• A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection — COMPLETED · PHASE3
• A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada — COMPLETED
• A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada — COMPLETED
• A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants — COMPLETED · PHASE3
• A PHASE 1/2A OPEN-LABEL DOSE-RANGING AND OBSERVER-BLIND PLACEBO-CONTROLLED, SAFETY AND IMMUNOGENICITY STUDY OF MRNA-1647 CYTOMEGALOVIRUS VACCINE IN FEMALE AND MALE PARTICIPANTS 9 TO 15 YEARS OF AGE AND PARTICIPANTS 16 TO 25 YEARS OF AGE — COMPLETED · PHASE1
• INFLUENCE OF A 3-MONTH LETERMOVIR TREATMENT ON GUT INFLAMMATION IN ART-TREATED HIV-INFECTED PERSONS IN AN OPEN LABELLED CONTROLLED RANDOMIZED STUDY — COMPLETED
• Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir — COMPLETED · PHASE3
• Study of SHP620 (Maribavir) in Healthy Adults — COMPLETED · PHASE1
• Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients — COMPLETED · PHASE2
• RANDOMIZED CONTROLLED TRIAL OF VALGANCICLOVIR FOR CYTOMEGALOVIRUS INFECTED HEARING IMPAIRED INFANTS (VALEAR TRIAL) — NOT_YET_RECRUITING
• Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation — COMPLETED · PHASE2
• Clinical Performance Evaluation of DxN CMV Assay — TERMINATED
• Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria — COMPLETED · PHASE4
• A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF MARIBAVIR TREATMENT COMPARED TO INVESTIGATOR-ASSIGNED TREATMENT IN TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS (CMV) INFECTIONS THAT ARE REFRACTORY OR RESISTANT TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, FOSCARNET, OR CIDOFOVIR — COMPLETED · PHASE3
• Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients — COMPLETED
• A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BRINCIDOFOVIR (BCV) VERSUS VALGANCICLOVIR (VGCV) FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN CMV-SEROPOSITIVE KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED ANTILYMPHOCYTE INDUCTION THERAPY — NOT_YET_RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF 28 WEEKS OF BRINCIDOFOVIR (BCV) VERSUS VALGANCICLOVIR (VGCV) FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN HIGH-RISK KIDNEY ALLOGRAFT RECIPIENTS — NOT_YET_RECRUITING · PHASE3
• The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment — COMPLETED
• Review of Human Herpes Viruses in Burns — COMPLETED
• Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age — COMPLETED · PHASE1
• Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) — COMPLETED · PHASE3

Refine this search